Astaxanthin Repeating Unit Polymers for Medical Device Coatings
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current astaxanthin-based polymers have limited bioactivity due to insufficient controlled release effects and are not suitable for localized medical applications, as they contain only a single astaxanthin unit, which restricts their use in medical devices that require biocompatibility, antimicrobial activity, and prevention of thrombus formation.
Innovation Solution
Development of polymers with a monomeric repeating unit comprising multiple astaxanthin moieties (-[ATX]n-) that are chemically bonded or associated, allowing for enhanced bioactivity and tailored properties such as mechanical, chemical, and microbial stability, and controlled release of astaxanthin, suitable for medical device coatings.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If a single astaxanthin unit is used in the polymer, then the polymer structure is simple, but the bioactivity and controlled release effects are insufficient
Solution Approach 1:
The patent divides the polymer structure into repeating units, each containing multiple astaxanthin moieties. This segmentation allows the polymer to maintain structural simplicity through repetition while significantly enhancing bioactivity through cumulative astaxanthin units. The repeating unit structure -[ATX]n- enables systematic accumulation of active components without complexifying the overall polymer architecture.
Solution Approach 2:
The patent merges multiple astaxanthin units into a single polymer structure through chemical bonding. This combining approach consolidates the bioactivity of individual ATX units into a unified polymer system, enabling enhanced controlled release effects and improved reliability while maintaining structural coherence through the repeating unit design.
2Reliability
If multiple astaxanthin units are incorporated into the polymer, then the bioactivity and controlled release effects are enhanced, but the polymer synthesis complexity increases
Solution Approach 1:
The patent employs a universal repeating unit structure -[ATX]n- that can be applied across different polymer types and applications. This multi-functional design allows the same basic unit to provide enhanced bioactivity while maintaining compatibility with various synthesis methods and application scenarios, thereby reducing the need for complex synthesis procedures for different configurations.
Solution Approach 2:
The patent utilizes parameter changes in the repeating unit structure, where n represents the number of astaxanthin moieties per unit. By varying this parameter rather than redesigning the entire polymer structure, the system achieves enhanced bioactivity through controlled release effects while maintaining a consistent, manageable synthesis approach based on the fundamental repeating unit.
3Productivity
If astaxanthin is used as a catalyst in polymerization, then the polymerization reaction proceeds, but the astaxanthin remains in small quantities and the reaction time is excessively long
Solution Approach 1:
The patent incorporates astaxanthin units directly into the polymer structure during the polymerization process rather than using it merely as a catalyst that remains separate. This preliminary action of integrating ATX into the forming polymer chain ensures that the active compound is present in significant quantities from the outset, eliminating the need for prolonged reaction times to accumulate sufficient ATX through catalytic action alone.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides a polymer having a repeating unit comprising at least one astaxanthin moiety, including processes for its preparation and various uses thereof.